Andreas F Hottinger
Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study.
Jörger M, Hundsberger T, Haefliger S, von Moos R, Hottinger A, Kaindl T, Engelhardt M, Marszewska M, Lane H, Roth P, Stathis A. Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study. Invest New Drugs 2023; 41:267-275.
16.02.2023Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study.
16.02.2023Invest New Drugs 2023; 41:267-275
Jörger Markus, Hundsberger Thomas, Haefliger Simon, von Moos Roger, Hottinger Andreas F, Kaindl Thomas, Engelhardt Marc, Marszewska Michalina, Lane Heidi, Roth Patrick, Stathis Anastasios
MRI and FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial
Wirsching H, Tabatabai G, Ochsenbein A, Roth P, Remonda L, Conen K, Caparrotti F, von Moos R, Hottinger A, Hundsberger T, Weller J, Roelcke U, Weller M. MRI and FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial. Clin Cancer Res 2020; 27:179-188.
23.09.2020MRI and FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial
23.09.2020Clin Cancer Res 2020; 27:179-188
Wirsching Hans-Georg, Tabatabai Ghazaleh, Ochsenbein Adrian, Roth Patrick, Remonda Luca, Conen Katrin, Caparrotti Francesca, von Moos Roger, Hottinger Andreas F, Hundsberger Thomas, Weller Jonathan, Roelcke Ulrich, Weller Michael
A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults
Roth P, Hofer S, Pesce G, Roelcke U, Mamot C, Reinert M, Schucht P, Läubli H, Hundsberger T, Hottinger A, Weller M. A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults. Swiss Med Wkly 2020; 150:w20256.
18.06.2020A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults
18.06.2020Swiss Med Wkly 2020; 150:w20256
Roth Patrick, Hofer Silvia, Pesce Gianfranco, Roelcke Ulrich, Mamot Christoph, Reinert Michael, Schucht Philippe, Läubli Heinz, Hundsberger Thomas, Hottinger Andreas F, Weller Michael
Impact of treatment decision algorithms on treatment costs in recurrent glioblastoma: a health economic study
Panje C, Putora P, Hundsberger T, Hottinger A, Roelcke U, Pesce G, Herrmann E, Matter-Walstra K. Impact of treatment decision algorithms on treatment costs in recurrent glioblastoma: a health economic study. Swiss Med Wkly 2019; 149:w20153.
02.12.2019Impact of treatment decision algorithms on treatment costs in recurrent glioblastoma: a health economic study
02.12.2019Swiss Med Wkly 2019; 149:w20153
Panje Cédric, Putora Paul Martin, Hundsberger Thomas, Hottinger Andreas F, Roelcke Ulrich, Pesce Gianfranco, Herrmann Evelyn, Matter-Walstra Klazien
Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management
Astaras C, de Micheli R, Moura B, Hundsberger T, Hottinger A. Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management. Curr Neurol Neurosci Rep 2018; 18:3.
01.02.2018Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management
01.02.2018Curr Neurol Neurosci Rep 2018; 18:3
Astaras Christophoros, de Micheli Rita, Moura Bianca, Hundsberger Thomas, Hottinger Andreas F
[Neurological complications of anticancer treatments]
Hottinger A, Perez L, Hägele-Link S, Hundsberger T. [Neurological complications of anticancer treatments]. Rev Med Suisse 2016; 12:840-3.
27.04.2016[Neurological complications of anticancer treatments]
27.04.2016Rev Med Suisse 2016; 12:840-3
Hottinger Andreas F, Perez Lyat, Hägele-Link Stefan, Hundsberger Thomas
Low-grade gliomas in adult patients
Kratzsch T, Gautschi O, Kuhn S, Hottinger A, Hildebrandt G, Stienen M. Low-grade gliomas in adult patients. Praxis (Bern 1994) 2014; 103:1385-1396.
01.11.2014Low-grade gliomas in adult patients
01.11.2014Praxis (Bern 1994) 2014; 103:1385-1396
Kratzsch Tobias, Gautschi Oliver P, Kuhn Susanne A, Hottinger Andreas F, Hildebrandt Gerhard, Stienen Martin N.
Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials
Hofer S, Wick W, Zander T, Weder P, Roelcke U, Pichler J, Ochsenbein A, Marosi C, Lemke D, Huber U, Hottinger A, Greil R, Elandt K, Weller M. Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. Acta Oncol 2011; 50:630-5.
18.04.2011Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials
18.04.2011Acta Oncol 2011; 50:630-5
Hofer Silvia, Wick Wolfgang, Zander Thilo, Weder Patrik, Roelcke Ulrich, Pichler Josef, Ochsenbein Adrian, Marosi Christine, Lemke Dieter, Huber Urs, Hottinger Andreas F, Greil Richard, Elandt Katarzyna, Weller Michael